
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded otic solution containing chloramphenicol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing chloramphenicol are listed in injection form, all for intravenous use. None of the FDA-approved chloramphenicol products is for use in the ear.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Chloramphenicol is a broad-spectrum antibiotic that compounding pharmacies prepare as sterile eye drops, ear drops and other topical preparations by prescription.
Chloramphenicol is a broad-spectrum antibiotic. It binds the 50S subunit of the bacterial ribosome and blocks protein synthesis; it mainly stops bacterial growth but can kill bacteria at high concentrations. The current manufactured human product on DailyMed is chloramphenicol sodium succinate for injection (Fresenius Kabi), FDA-approved only for serious infections when less dangerous drugs are ineffective or contraindicated, including typhoid fever, serious Salmonella, Haemophilus influenzae (especially meningitis), rickettsial and other susceptible Gram-negative infections, and in cystic fibrosis regimens. An older Chloromycetin ophthalmic ointment label also remains on DailyMed. StatPearls describes chloramphenicol eye drops, ear drops and eye ointment used for bacterial conjunctivitis and otitis externa, forms not offered by the manufactured injection. A prescriber may order chloramphenicol compounded in one of these topical forms. Compounded preparations are not FDA-approved and require a prescription.
Chloramphenicol injection carries an FDA boxed warning: serious and fatal blood disorders, including aplastic anemia, low platelets and low white cells, have occurred after short or long courses, and some cases of aplastic anemia later turned into leukemia. It must not be used for minor infections, colds, flu, throat infections or to prevent infection, and blood tests are needed during treatment. The chloramphenicol eye ointment label also carries a boxed warning that bone marrow hypoplasia, including aplastic anemia and death, has been reported after topical use. Do not use it if you have had an allergic or toxic reaction to chloramphenicol; StatPearls also lists acute porphyria as an absolute contraindication. Avoid other drugs that suppress the bone marrow. Newborns, especially premature infants, can develop "gray syndrome," a potentially fatal reaction, including after exposure during labor. Chloramphenicol crosses the placenta and passes into breast milk; LactMed reports vomiting, gas and sleepiness in nursing infants and prefers another drug. For unusual bleeding, bruising, fever, sore throat or vision changes, talk to your prescriber or pharmacist.
Chloramphenicol is bacteriostatic, and bactericidal at high concentrations, binding the 50S ribosomal subunit and blocking tRNA attachment at the A site. Per the injection label, it distributes widely, with the highest concentrations in liver and kidney, enters cerebrospinal fluid even without meningeal inflammation at about half the blood level, and reaches the aqueous and vitreous humors. It is inactivated by hepatic glucuronidation; neonates lack enough UDP-glucuronyltransferase, which underlies gray syndrome. Labeled indication: chloramphenicol sodium succinate injection for serious infections when less dangerous agents are ineffective or contraindicated. StatPearls describes ophthalmic and otic use for bacterial conjunctivitis and otitis externa and perioperative eye ointment, and notes ototoxicity with ear drops. Dosing per prescriber. The label calls adequate blood studies essential during treatment but notes they cannot be relied on to detect marrow depression before aplastic anemia. StatPearls recommends plasma level monitoring with systemic use, especially in the elderly, young children and hepatic impairment, plus baseline and routine CBC, renal and liver function. StatPearls also cautions against coadministration with rifampicin, carbimazole and trimethoprim. Chloramphenicol is not a controlled substance.
Wash your hands. Warm the bottle in your hand for a few minutes, since cold drops can cause dizziness. Lie on your side or tilt your head so the affected ear faces up. Pull the ear up and back (back and down for a young child) and place the number of drops on your label into the canal without touching the dropper tip to your ear. Stay in position for a few minutes. Recap and wash your hands. Do not use drops that have changed color or turned cloudy.
Otic solutions are aqueous or glycerin based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place drops into affected ear(s)